FDMT 4D Molecular Therapeutics, Inc.
8-K Current Report
Filed: March 18, 2026
Health Care
Biological Products, (No Diagnostic Substances)4D Molecular Therapeutics, Inc. (FDMT) 8-K current report filed with SEC EDGAR on March 18, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 2.02: Results of Operations and Financial Condition
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Full year 2025 financial results announced, details in press release titled “4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones”
- • Press release furnished as Exhibit, key financial and operational updates available there
Get deeper insights on 4D Molecular Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.